Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis

E. Kouhsari, N. Sadeghifard, A. Khadiv, H. Sayadi, T. Amiriani, S. Ghafourian, H. Valadbeigi, M. Krutova

. 2022 ; 21 (1) : 19. [pub] 20220520

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, metaanalýza, přehledy, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018350

BACKGROUND: Antimicrobial resistance of H. pylori can lead to treatment failure. Importantly, several studies have reported on heteroresistance, i.e. the presence of resistant and susceptible H. pylori populations in the same sample and/or a difference in the susceptibility patterns between biopsy samples. This meta-analysis aims to provide comprehensive data on the prevalence of metronidazole and clarithromycin heteroresistance and the approaches to their detection. MATERIAL AND METHODS: A systematic review was performed after the search of MEDLINE, Scopus and Web of Science. The study outcomes were the weighted pooled prevalence of heteroresistance to clarithromycin and metronidazole in H. pylori positive samples and/or isolates with a subanalysis by continent. RESULTS: A total of 22 studies that had investigated 3852 H. pylori positive patients were included in the meta-analysis. Heteroresistance to clarithromycin was reported in 20 studies, with a weighted pooled prevalence of 6.8% (95% CI 5.1-8.6; 3654 H. pylori positive patients; the substantial heterogeneity I2 = 55.6%). Heteroresistance to metronidazole was reported in 12 studies, with a weighted pooled prevalence of 13.8% (95% CI 8.9-18.6; 1670 H. pylori positive patients; the substantial heterogeneity I2 = 60.9%). The weighted pooled prevalence of clarithromycin heteroresistance was similar in Asia and Europe (p = 0.174584), however, metronidazole heteroresistance was detected more often in Europe (p < 0.00001). Clarithromycin heteroresistance was detected more often by phenotype rather than by using genotyping methods (12 vs 8 studies), whereas heteroresistance to metronidazole was detected only by phenotype. CONCLUSION: The prevalence of heteroresistance to clarithromycin and/or metronidazole is not negligible and can be detected in approximately 7 and 14% of H. pylori positive samples, respectively. These findings highlight the need to raise the awareness of gastroenterologists and microbiologists to the heteroresistance to clarithromycin and metronidazole in patients with a H. pylori infection.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018350
003      
CZ-PrNML
005      
20220804134723.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12941-022-00509-3 $2 doi
035    __
$a (PubMed)35596211
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kouhsari, Ebrahim $u Laboratory Sciences Research Centre, Golestan University of Medical Sciences, Gorgan, Iran
245    10
$a Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis / $c E. Kouhsari, N. Sadeghifard, A. Khadiv, H. Sayadi, T. Amiriani, S. Ghafourian, H. Valadbeigi, M. Krutova
520    9_
$a BACKGROUND: Antimicrobial resistance of H. pylori can lead to treatment failure. Importantly, several studies have reported on heteroresistance, i.e. the presence of resistant and susceptible H. pylori populations in the same sample and/or a difference in the susceptibility patterns between biopsy samples. This meta-analysis aims to provide comprehensive data on the prevalence of metronidazole and clarithromycin heteroresistance and the approaches to their detection. MATERIAL AND METHODS: A systematic review was performed after the search of MEDLINE, Scopus and Web of Science. The study outcomes were the weighted pooled prevalence of heteroresistance to clarithromycin and metronidazole in H. pylori positive samples and/or isolates with a subanalysis by continent. RESULTS: A total of 22 studies that had investigated 3852 H. pylori positive patients were included in the meta-analysis. Heteroresistance to clarithromycin was reported in 20 studies, with a weighted pooled prevalence of 6.8% (95% CI 5.1-8.6; 3654 H. pylori positive patients; the substantial heterogeneity I2 = 55.6%). Heteroresistance to metronidazole was reported in 12 studies, with a weighted pooled prevalence of 13.8% (95% CI 8.9-18.6; 1670 H. pylori positive patients; the substantial heterogeneity I2 = 60.9%). The weighted pooled prevalence of clarithromycin heteroresistance was similar in Asia and Europe (p = 0.174584), however, metronidazole heteroresistance was detected more often in Europe (p < 0.00001). Clarithromycin heteroresistance was detected more often by phenotype rather than by using genotyping methods (12 vs 8 studies), whereas heteroresistance to metronidazole was detected only by phenotype. CONCLUSION: The prevalence of heteroresistance to clarithromycin and/or metronidazole is not negligible and can be detected in approximately 7 and 14% of H. pylori positive samples, respectively. These findings highlight the need to raise the awareness of gastroenterologists and microbiologists to the heteroresistance to clarithromycin and metronidazole in patients with a H. pylori infection.
650    _2
$a amoxicilin $x farmakologie $7 D000658
650    _2
$a antibakteriální látky $x farmakologie $x terapeutické užití $7 D000900
650    _2
$a klarithromycin $x farmakologie $x terapeutické užití $7 D017291
650    _2
$a bakteriální léková rezistence $x genetika $7 D024881
650    12
$a infekce vyvolané Helicobacter pylori $x diagnóza $x farmakoterapie $7 D016481
650    12
$a Helicobacter pylori $7 D016480
650    _2
$a lidé $7 D006801
650    _2
$a metronidazol $x farmakologie $x terapeutické užití $7 D008795
650    _2
$a mikrobiální testy citlivosti $7 D008826
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a přehledy $7 D016454
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Sadeghifard, Nourkhoda $u Clinical Microbiology Research Centre, Ilam University of Medical Sciences, Ilam, Iran
700    1_
$a Khadiv, Arezoo $u Clinical Microbiology Research Centre, Ilam University of Medical Sciences, Ilam, Iran $u Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
700    1_
$a Sayadi, Hojjat $u Non-Communicable Diseases Research Centre, Ilam University of Medical Sciences, Ilam, Iran
700    1_
$a Amiriani, Taghi $u Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
700    1_
$a Ghafourian, Sobhan $u Clinical Microbiology Research Centre, Ilam University of Medical Sciences, Ilam, Iran $u Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
700    1_
$a Valadbeigi, Hassan $u Clinical Microbiology Research Centre, Ilam University of Medical Sciences, Ilam, Iran. hasan.valadbeigi@gmail.com
700    1_
$a Krutova, Marcela $u Department of Medical Microbiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
773    0_
$w MED00008163 $t Annals of clinical microbiology and antimicrobials $x 1476-0711 $g Roč. 21, č. 1 (2022), s. 19
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35596211 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134716 $b ABA008
999    __
$a ok $b bmc $g 1822107 $s 1169593
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 21 $c 1 $d 19 $e 20220520 $i 1476-0711 $m Annals of clinical microbiology and antimicrobials $n Ann Clin Microbiol Antimicrob $x MED00008163
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace